Patients with alkaline phosphatase that is > ULN but =< 2.5 x ULN or unexplained bone pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan performed within 90 days prior to randomization does not demonstrate metastatic disease
No lytic lesions on skeletal survey and whole body PET/CT other than a single lesion associated with solitary bone plasmacytoma within 28 days prior to registration
Patients must have a whole body or limited whole body PET/CT scan performed within 42 days prior to registration
All disease must be assessed and documented on the S1608 FDG-PET/CT assessment form
Patients unable to have an FDG-PET scan, either through insurance coverage, patient decision or other reason are not eligible for this study
Patients unable to have an FDG-PET/CT scan, either through insurance coverage, patient decision or other reason are not eligible for this study
PHASE II INCLUSION CRITERIA: Patients with tumor tissue uptake during NETSPOT PET that is equal to or higher than that in normal hepatic tissue (grade >= 2) will be eligible; it is recommended that NETSPOT PET be obtained before initiation of chemotherapy, but NETSPOT PET obtained during or after completion of chemotherapy could be used for screening purpose
Patients with alkaline phosphatase that is > ULN but less than or equal to 2.5 x ULN or with unexplained bone pain are eligible for inclusion in the study if bone imaging (bone scan, PET-CT scan, or PET scan) performed within 28 days prior to randomization does not demonstrate metastatic disease.
Patients must have measurable or evaluable disease that is FDG avid with standardized uptake value (SUV) > 3 on PET/CT
Measurable or evaluable disease, including at least one of the following: measureable tumor by CT or MRI; a positive MIBG, or PET scan; positive bone marrow biopsy/aspirate.
Appropriate diagnostic/staging workup, including:\r\n* Complete history and physical examination\r\n* Whole body PET/computed tomography (CT) scan within 42 days prior to study entry demonstrating hypermetabolic pulmonary lesion(s) and/or thoracic lymph node(s), with a maximum standardized uptake volume (SUV) > 6 for at least one lesion; if PET/CT was obtained more than 42 days prior to study entry and is not repeated, CT scan of the chest within 28 days prior to study entry demonstrating stable disease is required\r\n* Magnetic resonance imaging (MRI) of the brain or CT scan of the head with contrast within 42 days prior to study entry\r\n* Biopsy confirmation of suspected metastatic disease identified by PET/CT is recommended\r\n* Pulmonary function tests (PFTs) within 6 weeks of study entry are highly recommended but not required
Patients must be maintained on a stable corticosteroid regimen for 5 days prior each magnetic resonance (MR)-PET scan
Creatinine =< 2.5 (within 14 days of PET imaging)
Eligible and consent signed for imaging with AMT PET under protocol 2011-­053
Stage IIIB, or distant metastases (including malignant pleural effusion) identified on PET-CT scan or biopsy (PET abnormalities that are negative for malignancy on biopsy will be considered on a case by case basis
Bone marrow involvement based on PET/CT scan at screening
Tumor imaging and bone marrow evaluation for histologic analysis of marrow tumor cell quantity must be obtained within 4 weeks (28 days) prior to enrollment onto study; patients must have ONE of the following:\r\n* Measurable tumor on magnetic resonance imaging (MRI), computed tomography (CT), or x-ray; measurable is defined as minimum of 20 mm in at least one dimension; for patients who are in first response (i.e., those patients with persistent sites of tumor after frontline therapy but who have never relapsed), a biopsy of a lesion or bone marrow must demonstrate viable neuroblastoma cells or patients must have a lesion positive on iobenguane (MIBG) scan or positron emission tomography (PET) scan; if the lesion was irradiated, the MIBG scan, PET scan or biopsy must be done at least 4 weeks after radiation is completed\r\n* MIBG or PET scan with positive uptake at minimum of one site; if lesion was radiated, the scan must be done at least 4 weeks after radiation completed\r\n* Bone marrow with tumor cells seen on routine morphology of bilateral aspirate and/or biopsy on at least one bone marrow sample
Must have presence of SSTR+ disease as documented by positive Ga-68-DOTATATE PET scan within 26 weeks of anticipated treatment\r\n* NOTE:\r\n** Positivity of Ga-68-DOTATATE PET scan defined as having at least one lesion that is >= 10 mm in diameter with uptake that is higher than or equal to liver and is qualitatively higher and distinguishable from background activity\r\n** Measurable disease as defined by RECIST 1.1
A PET/CT scan is required within 12 weeks (plus/minus 1 week) of study registration. Any lymph node suspected of harboring disease based on its shape, size, or PET standardized uptake value (SUV) should be discussed by treating physician and diagnostic radiologist
PET-positive disease by Lugano classification
Bone marrow involvement based on CT or PET scan at screening
Uncontrolled diabetes (i.e., will interfere with the performance of the FDG PET/CT scans)
Assessment of all known disease sites, eg, by CT scan, MRI, bone scan as appropriate, and/or FDG-PET scan within 28 days before the first dose of cabozantinib
Measurable or evaluable disease, including at least one of the following: Measureable tumor by CT or MRI; or A positive MIBG or PET scan; or Positive bone marrow biopsy/aspirate.
Documented (signed) informed consent; the patient, family member and transplant staff physician (physician, nurse, and social worker) meet at least once prior to starting the transplant procedure; during this meeting all pertinent information with respect to risks and benefits to donor and recipient will be presented; alternative treatment modalities will be discussed:\r\n* A. No Research Imaging – for patients for whom one or more of the following applies:\r\n** Is a minor (< 18 years of age)\r\n** Acute lymphoblastic leukemia (ALL) diagnosis\r\n** Does not agree to optional imaging (WF-MRI, DECT)\r\n* B. With Research Imaging – all of the following must apply:\r\n** Adult (>= 18 years of age)\r\n** Acute myeloid leukemia AML diagnosis\r\n** Agree to optional imaging: WF-MRI and DECT\r\n** Do not agree to optional FLT-PET, or there are no FLT-PET slots available\r\n* C. With Research Imaging plus FLT-PET\r\n** Adult (>= 18 years of age)\r\n** AML diagnosis\r\n** Agrees to optional imaging: WF-MRI and DECT\r\n** Agrees to optional FLT-PET\r\n** FLT-PET accrual remains open
Fludeoxyglucose F 18 (FDG)-avid disease by FDG-PET/CT and measurable disease of at least 1.5 cm by CT
Systemic corticosteroids between pre-PET and post-PET evaluation and biopsy
Presence of metastatic disease is not allowed; subjects must be evaluated with imaging consisting of CT scan and PET scan prior to enrollment for protocol therapy to exclude metastatic disease
At least one but no more than 5 discrete PSMA-avid metastases on baseline PSMA-PET scan; all PSMA-avid lesions must be amenable to SBRT in judgment of treating radiation oncologist; there are no restrictions on site of metastasis (e.g. bone, lymph node, visceral); equivocal lesions on PSMA PET scan that are not definitive for metastasis will not count towards the limit of metastases and will not undergo SBRT
Patient agrees to undergo a baseline and a follow-up 11C-alpha-methyl-L-tryptophan (AMT)-PET scan during immunotherapy (IMT)
Resective surgery within 2 months prior to the initial pre-treatment AMT-PET scan
Patient must be able to tolerate imaging requirements of an 18-FDG-PET-CT scan
Patients with hypermetabolic para-aortic disease identified on baseline 18-FDG-PET-CT
PHASE II: The patient meets the criteria required for the imaging study in which the site is participating:\r\n* NOTE: Eligibility for participating in either imaging sub-study will depend on the availability of the imaging sub-study at a particular institution\r\n* For participation in the FDG-PET sub-study:\r\n** Patients must NOT have poorly controlled diabetes (defined as fasting glucose level >= 200 mg/dL) despite efforts to improve glucose control by fasting duration and adjustment of medications\r\n** Patient must NOT weigh more than the maximum weight limit for the PET table\r\n** Patients must have an evaluable lesion of > 20 mm in size on standard practice imaging study as assessed by site (either primary pancreas mass or metastasis)\r\n* For participation in the FLT-PET sub-study:\r\n** Patients must be able to lie still for a 1.5 hour PET scan.\r\n** Patient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-fluorothymidine\r\n** Patient must NOT weigh more than the maximum weight limit for the PET table\r\n** Patients must have an evaluable lesion in the pancreas > 20 mm in size on standard practice imaging study as assessed by site (lesion must be likely primary adenocarcinoma of the pancreas that is not primarily fibrotic or mucinous in nature)
Patients with alkaline phosphatase that is > ULN but =< 2.5 x ULN or unexplained bone pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan performed within 6 weeks prior to randomization does not demonstrate metastatic disease
Patients must have baseline PET scan within 28 days prior to registration; note that images are submitted centrally for review
FDG-PET/CT scan for staging and RT plan within 4 weeks prior to registration
Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination, including a neurological assessment, within 8 weeks of registration\r\n* Evaluation by a thoracic surgeon within 4 weeks of registration; the patient must be deemed potentially operable and resectable to be eligible for the study\r\n* Whole body fludeoxyglucose F 18 (FDG)-PET (or PET/CT) scan within 6 weeks of registration\r\n* A magnetic resonance imaging (MRI) with contrast of the brain (or CT scan with contrast of brain, if an MRI is medically contraindicated) within 5 weeks of registration\r\n* A CT scan with contrast of the lungs and upper abdomen to complete T and N staging and exclude other ipsilateral or contralateral parenchymal lesions and liver or adrenal metastases within 5 weeks of registration
Patients must have at least one measurable lesion that can be followed for response assessment on baseline imaging obtained no more than 28 days prior to beginning study therapy. Baseline and follow up radiological disease assessment must include bone scans performed with either Technetium-99m labeled diphosphonates or Fluorine-18 sodium fluoride PET or PET/CT, as per the local standard of care for patients with prostate cancer.
Pretreatment evaluations required for eligibility include:\r\n* A medical history, physical examination, assessment of Zubrod performance status within 4 weeks prior to study entry;\r\n* Complete blood count (CBC) with differential and platelet count, and laboratory profile must be completed within 4 weeks prior to study entry;\r\n* FEV1, CT scan or magnetic resonance imaging (MRI) of the chest, a bone scan (or positron emission tomography [PET] or PET/CT), and a CT scan or MRI of the brain (to rule out brain metastasis) within 6 weeks prior to study entry;\r\n* Medical Oncology and Radiation Oncology consults and approval
Patients must have a chest CT scan, or PET/CT scan to rule out metastatic disease
Bone marrow involvement based on CT or PET scan at screening
Patients must have at least ONE of the following:\r\n* Measurable tumor on magnetic resonance imaging (MRI), computed tomography (CT) scan obtained within 3 weeks prior to study entry; measurable is defined as >= 10 mm in at least one dimension on spiral/helical CT that is metaiodobenzylguanidine (MIBG) avid or demonstrates increased fludeoxyglucose (FDG) uptake on positron emission tomography (PET) scan\r\n* MIBG scan obtained within 3 weeks prior to study entry with positive uptake at a minimum of one site; this site must represent disease recurrence after completion of therapy, progressive disease on therapy, or refractory disease during induction\r\n* Patients with resistant/refractory soft tissue disease that is not MIBG avid or does not demonstrate increased FDG uptake on PET scan must undergo biopsy to document the presence of viable neuroblastoma; biopsy is not required for patients who have new site of soft tissue disease (radiographic evidence of disease progression) regardless of whether progression occurs while receiving therapy or after completion of therapy\r\n* Note: Patients with elevated catecholamines (i.e., > 2 x ULN) only or bone marrow disease only are NOT eligible for this study
DCFPyL-PET/MRI or DCFPyL-PET/CT scan within the past 6 months with results that demonstrate more disease lesions than baseline CT/bone scan
Complete remission (CR) according to the Revised Response Criteria for Malignant Lymphoma after first-line treatment\r\n* Diagnostic CT scans with contrast of chest, abdomen, and pelvis must have been performed within 8 weeks from the first day of the last cycle of R-chemotherapy; a neck CT will be required if the patient had involvement of the neck region at initial diagnosis\r\n* A negative fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/CT scan performed within 8 weeks from the first day of the last cycle of R-chemotherapy and confirming CR, with negative defined as a score of 1-3 on the Deauville 5-point scale used to quantify radionucleotide density in PET scans as determined locally; PET positive/indeterminate lesions which are confirmed on biopsy to harbor no active lymphoma will be considered negative for determination of CR status\r\n* If positive bone marrow involvement at initial diagnosis the patient must have a negative bone marrow biopsy following R-chemotherapy to confirm the CR
Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm by CT
Patients may have had one cycle only of ABVD prior to enrolling on study; no other prior treatment (chemotherapy or radiation therapy) for Hodgkin lymphoma is allowed; if patient has had one cycle of ABVD, in order to be eligible to enroll on Cancer and Leukemia Group B (CALGB) 50801, the patient must have had all of the following tests prior to starting the first cycle of ABVD:\r\n* Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multi gated acquisition (MUGA)\r\n* Pulmonary function tests (PFTs) (including diffusing capacity of the lung for carbon monoxide [DLCO]/forced vital capacity [FVC])\r\n* CT scan (neck**, chest, abdomen, pelvis)\r\n* FDG-PET/CT scan\r\n* Chest X-ray, posterior-anterior (PA) & lateral\r\n* Complete blood count (CBC), differential, platelets\r\n* Erythrocyte sedimentation rate (ESR)\r\n* Serum creatinine\r\n* Glucose\r\n* Aspartate aminotransferase (AST)\r\n* Alkaline phosphatase\r\n* Bilirubin\r\n* Lactate dehydrogenase (LDH)\r\n** Patients with a negative FDG-PET/CT scan do not need to have had a dedicated neck CT scan prior to starting the previous cycle of ABVD
Residual FDG-PET activity defined as Deauville 4 or 5 on a PET-CT within 3 and 8 weeks post the last dose of front line therapy
Disease progression: FDG avid malignancy that is classified as an FDG PET non-responder\r\n* PET non-responders are defined as having < 35% reduction in the FDG uptake of the primary tumor when compared to baseline
Patients must have an avid primary tumor with an standardized uptake value (SUV) of >= 5 on baseline (18F) FDG-PET/computed tomography (CT) imaging
FDG PET-CT (disease) positive baseline scan with measurable disease.
Use of drugs to treat or prevent herpesvirus infections, including ganciclovir, acyclovir, valacyclovir, valganciclovir, foscarnet, cidofovir, and adefovir, must be stopped >= 24 hours prior to the baseline [124I]FIAU-PET-CT scan and cannot be resumed until after the last [124I]FIAU-PET-CT scan
Patients are eligible with untreated squamous, adenosquamous, or adenocarcinoma cancers of stage IB2-IVA carcinoma of the uterine cervix or stage II-IVA vaginal carcinoma not amenable to curative surgical resection; pathological verification of diagnosis must be obtained and recorded; the presence or absence of para-aortic lymph node metastasis will be based on pre-therapy 18F-FDG PET/CT; if the baseline 18F-FDG PET/CT identifies hypermetabolic para-aortic disease, such patients will not be eligible for participation; the patient must be able to tolerate the requirements for 18F-FDG PET/CT scanning
FDG-PET avid (only if tumor known to be MIBG non-avid). These patients must have had a biopsy confirming neuroblastoma and/or ganglioneuroblastoma in at least one FDG-PET avid site present at the time of enrollment done prior to enrollment and at least two weeks subsequent to the most recent prior therapy.
All patients must have undergone staging of their lung cancer prior to enrollment with a chest CT scan and PET scan, both within 8 weeks of inclusion, in addition to bronchoscopy
Measurable disease by Non-Hodgkin’s Lymphoma Response Criteria on FDG-PET/CT; baseline measurements and evaluations must be obtained =< 21 days prior to registration
Fludeoxyglucose F-18 (FDG)-avid disease by FDG-PET/computed tomography (CT)
For Arm 1 patients, the time from the TRUS prostate biopsy to the planned first study PET scan must be >= 1 month; for patients who have undergone prior prostate mapping biopsy, the time from the mapping biopsy to the planned first study PET scan must be >= 2 months
Cytotoxic chemotherapy within 4 weeks of first planned study PET/CT scan
Filgrastim (G-CSF) therapy within 10 days of the first planned research PET/CT scan
Patient must be able to lie still for a 20-30 minute PET/CT scan
Patient must be maintained on a stable corticosteroid regimen for 5 days prior to each MR-PET scan
Negative technetium 99-m methylene diphosphonate (MDP) or F-18 PET bone scan for skeletal metastasis
Patients on corticosteroids must be maintained on a stable corticosteroid regimen for 5 days prior each magnetic resonance (MR)-PET scan
Scheduled for or completed a 18F-FDG-PET or 18F-FDG-PET/CT tumor staging procedure
Patients less than 3 years of age who require a total length of anesthesia time greater than 3 hours (for the 18F-fluorodopamine [FLO]PET scan in conjunction with another clinical procedure requiring sedation) will be excluded from the study
Severe/uncontrolled inter current illness within the previous 28 days prior to PET scan
Axumin PET/CT scan already performed or scheduled as best standard of care procedure for suspected disease relapse within 2 weeks before or after intended 68Ga-PSMA-11 PET/CT
Any change in prostate cancer treatment between Axumin and 68Ga-PSMA PET/CT scan
Whole body 18F-FDG PET/computed tomography (CT) or I-131 scintigraphy within the past 90 days of the scheduled 68Ga-PSMA PET demonstrating uptake
Participant must have undergone a PET/computed tomography (CT) examination with injection of a standard dose of 18F-fluorodeoxyclucose (FDG) or other PET tracer with a half-life greater than one hour either for clinical or research purposes within 3 hrs of the proposed PET-MRI examination
Patient must be able to lie still for a 20 to 30 minute PET/CT scan
Ability to undergo standard PET imaging; an 18 F FDG PET/CT scan will take place within 8 weeks of enrollment
Patients who are too claustrophobic to undergo PET scanning
Platelets >= 100,000/mm^3, obtained within 14 days prior to C11-AMT PET scan
Serum total bilirubin =< 1.5 x ULN, obtained within 14 days prior to C11-AMT PET scan
Adjuvant anticancer treatments are allowed if at least 30 days has elapsed between the infusion/injection and C11-AMT PET scan as part of this study
Patient must be able to lie still for a 20 to 30 minute PET/CT scan.
Biopsy proven or clinically documented metastatic breast cancer with at least one lesion outside the liver by standard imaging (e.g. CT, magnetic resonance imaging [MRI], bone scan, ultrasound, fludeoxyglucose F 18 [FDG] PET/CT)
Agreed to FLT-PET imaging and signed consent and eligible FLT-PET protocol 2006-127
Patients with NSCLC diagnosis who have been referred for a clinical FDG PET/CT staging scan as part of their standard of care
No evidence of metastatic disease on conventional imaging, including a negative bone scan for skeletal metastasis and negative contrast-enhanced CT; sodium fluoride (NaF) PET CT can substitute for separate bone scan and CT
Able to complete a PET/CT scan without the use of sedation
The patient must provide informed written consent, which will include a layman’s explanation of the estimated amount of additional radiation that the patient will receive from the investigational PET/CT scan using 18F-FSPG
A recognized active lung infection (this will confound the standard-of-care 18F-FDG PET/CT scan)
Peptide receptor radionuclide therapy (PRRT) within 4 weeks of Ga-68 DOTATOC PET/CT scan
Study subjects will have undergone or are scheduled for PET-CT and/or bone scan within about 2 weeks of the WB and primary tumor DWI MRI
Recurrent or metastatic cancer that is of known or suspected breast origin - may be biopsy proven or identified on standard imaging (e.g. CT, bone scan, magnetic resonance imaging [MRI], FDG PET/CT)
At least one site of disease outside of the liver that is seen on standard imaging (e.g. CT, bone scan, MRI, FDG PET/CT); patients with measurable or nonmeasurable disease are allowed
Baseline FDG-PET/CT scans must demonstrate at least one hypermetabolic lesion as defined by the Deauville criteria localizing to CT-defined anatomical tumor sites
Patients who require sedation for imaging studies will be excluded from the FLT PET scan research test; they will undergo only the standard of care MRI and FDG PET scan
Patients must be willing and able to adhere to a special low-carb diet 24-48 hours prior to and fast 8-12 hours prior to every 18F-FDG PET scan
Radiologic evidence of new or progressive metastatic disease demonstrated on anatomical imaging (CT, magnetic resonance imaging [MRI], or ultrasound), bone scintigraphy, fluorine F 18 sodium fluoride ([18F]sodium fluoride) PET, and/or fludeoxyglucose F 18 ([18F]FDG) PET
Prostate biopsy within 6 weeks prior to PET or MRI imaging
Able to cooperate for the PET CT scan when registered on study
Patient may have had a prior PET or PET/CT scan for staging/restaging.
Patient’s tumor(s) must be FDG avid on baseline standard of care FDG-PET/CT or PET/MR imaging that was performed at Barnes-Jewish Hospital Clinical PET Facility
If the patient will be scanned on the PET/MR for the mid-treatment scan, they must be determined to be safe for exposure to the magnetic field; this will be determined the day of imaging by the technologist with the use of a screening form; if a patient is not safe for the PET/MR scanner, their mid-treatment images will occur on the PET/CT scanner in the Center for Clinical Imaging Research
Patients must have disease with FDG-PET/CT avidity
Participant must be able to complete a PET/CT scan and MRI without the use of sedation
All pathology specimens must be within 1 year of the planned 18F-FSPG PET/CT scan.
Uncontrolled diabetes or blood glucose > 180 mg/dl on the day of the fludeoxyglucose F 18 ([18F]FDG)-PET scan
Cancer patients receiving radiation treatment to the thorax to at least 45 Gy; patient must have pathologic confirmation of diagnosis, or have an enlarging lung mass on at least two scans spaced 3 months apart, and FDG avidity on PET scan
Any biopsy proven HER2-positive malignancy; American Society of Clinical Oncology (ASCO) guidelines will be used to define HER2-positivity for breast cancer; similar guidelines will be used for other cancer types as appropriate; at least one malignant lesion on CT, magnetic resonance (MR), or fludeoxyglucose (FDG) PET/CT within 60 days of protocol enrollment
Patients should have no contraindications for FDG-PET/CT
Metastatic workup\r\n* Whole body sodium fluoride (NaF) PET/(CT) computed tomography or 99mTc bone scan
Pretreatment evaluations required for eligibility include:\r\n* A medical history, physical examination, weight, assessment of ECOG performance status within 4 weeks prior to study entry;\r\n* Evaluation by an experienced thoracic cancer clinician within 8 weeks prior to study entry;\r\n* For women of childbearing potential, a serum or urine pregnancy test must be performed within 72 hours prior to the start of protocol treatment;\r\n* CT scan (preferably with intravenous contrast, unless medically contraindicated) to include the entirety of both lungs, the mediastinum, liver, and adrenal glands; primary tumor dimension will be measured on CT;\r\n* Whole body positron emission tomography (PET)/CT scan using fludeoxyglucose (FDG)-18 with adequate visualization of the primary tumor and draining lymph node basins in the hilar and mediastinal regions; \r\n* Ability to understand and the willingness to sign written informed consent document
Patient will be undergoing a FDG-PET scan as part of staging or response assessment for malignancy; Note: the patient may be newly-diagnosed, currently receiving therapy, or have already completed therapy; the presence of identifiable tumor on the PET scan is not required
Evidence of metastatic disease demonstrated by an abnormal bone scan, CT scan, MRI and/or FDG-PET scan within 6 weeks (with no further interval treatment before imaging trial)
Participant is scheduled for standard clinical and/or investigational PET/CT scan or 131 I therapy within the Nuclear Medicine Service at Main Hospital
Radiation treatment to bone less than 4 weeks from the first PET scan
Radiopharmaceutical treatment to bone less than 4 weeks from first PET scan
